Retisert

HELP YOUR PATIENTS OBTAIN ACCESS TO RETISERT®*

Ordering made easy:

RETISERT® can be ordered Monday-Friday 8am-5pm EST

CALL

Bausch Health Customer Service, 800-321-4576 then press 7

PLACE

an order and it will be shipped the next day

Patient assistance program*

FOCUS ON ACCESS™ (FOA) helps patients secure access to RETISERT ® and offers the following services*:

  • Reimbursement counseling on insurance coverage availability for RETISERT®*
  • Patient assistance for eligible patients without insurance coverage or if the product is not covered by their insurance plan*

*Terms and conditions apply and can be found on the FOA enrollment form. Please be sure to share eligibility criteria with your patients.

Printable resources for your patients:

ENROLLMENT FORM

Download the FOA savings program enrollment form for your patients

FOA CARD

Print FOA information card for
your patients

For information on reimbursement and patient assistance services

Call the FOCUS ON ACCESS™ Hotline: 1 (866) 272-8838

(Monday-Friday, 9 AM to 5 PM EST).

Resources are available for your patients

Indication

RETISERT® (fluocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.

Important Safety Information

  • Surgical placement of RETISERT® (fluocinolone acetonide intravitreal implant) 0.59 mg is contraindicated in active viral, bacterial, mycobacterial or fungal infections of the eye.
  • Based on clinical trials with RETISERT®, during the 3-year post-implantation period, nearly all phakic eyes are expected to develop cataracts and require cataract surgery.
  • As with any surgical procedure, there is risk involved. Potential complications accompanying intraocular surgery to place RETISERT® into the vitreous cavity may include, but are not limited to, the following: cataract formation, choroidal detachment, endophthalmitis, hypotony, increased intraocular pressure, exacerbation of intraocular inflammation, retinal detachment, vitreous hemorrhage, vitreous loss, and wound dehiscence.
  • Following implantation of RETISERT®, nearly all patients will experience an immediate and temporary decrease in visual acuity in the implanted eye which lasts for approximately one to four weeks post-operatively.
  • Use of corticosteroids may result in elevated IOP and/or glaucoma. Based on clinical trials with RETISERT®, within 3 years post-implantation, approximately 77% of patients will require IOP lowering medications to control intraocular pressure and 37% of patients will require filtering procedures to control intraocular pressure.
  • Patients should be advised to have ophthalmologic follow-up examinations of both eyes at appropriate intervals following implantation of RETISERT®. Physicians should periodically monitor the integrity of the implant by visual inspection.
  • Ocular administration of corticosteroids has been associated with delayed wound healing and perforation of the globe where there is thinning of the sclera.
  • The most frequently reported ocular adverse events in clinical trials with RETISERT® occurring in 50-90% of patients included: cataract, increased intraocular pressure, procedural complications and eye pain. The most common non-ocular event reported was headache (33%).

Click here for full Prescribing Information for RETISERT®.

References: 1. RETISERT [Package Insert]. Rochester, NY: Bausch & Lomb Incorporated.; May 2019.

Indication and Important Safety Information